The volatility of the drug approval process is evident in the latest novel drug statistics, which show agency approval for new drugs in 2018 is down 44 percent compared with this time last year.
In 2017, the Food and Drug Administration had cleared 18 novel medicines by April, Bob Kirby, a lead pharmaceutical analyst at Fitch Ratings Inc., wrote in a report published June 6. So far, the agency has cleared 10 novel drugs in the first four months of 2018.
Kirby’s analysis shouldn’t be taken as a sign that the FDA is being less effective. It’s more of a testament to how we should be wary of making huge judgments based on numerical swings in drug approval numbers year to year. Because in the world of drug approvals, volatility is the name of the game.
Take the changes year to year in new medicines the FDA approved in the last few years. The agency approved 22 novel drugs in 2016, compared with 45 in 2015 and 46 in 2017. Does it mean the agency was slacking off in 2016? Not necessarily, Kirby says.
"Over time we will see volatility," he said, "but really as long as the industry keeps investing in research and development and is successful at it, we should see a normalized kind of growth."
And the FDA is all too willing to point out that its ability “to sustain a steady increase in annual approvals is dependent on a steady increase in the number of applications submitted," Sandy Walsh, one of the agency’s press officers for the Office of External Affairs, told me.
Kirby’s analysis comes as drug pricing sits at center stage in a national conversation about the affordability of health care. Faster drug approvals has been a priority for FDA's leader Scott Gottlieb since he took over as commissioner of the agency in May 2017.
Stay on top of new developments in health law and regulation, and learn more, by signing up for a free trial to Bloomberg Law.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to firstname.lastname@example.org.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to email@example.com.
Put me on standing order
Notify me when new releases are available (no standing order will be created)